Related Experiment Videos
Recent clinical trial highlights in hypertension
1Franz Volhard Clinic and Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Humboldt University of Berlin, Wiltberg Strasse 50, 13125 Berlin, Germany. luft@fvk.berlin.de
Insights
Clinical trials inform patient care, but hypotheses often lack diversity, especially for women. Current hypertension treatments may be insufficient for many patients, necessitating further research into effective management strategies.
Area of Science:
- Cardiology and Hypertension Research
- Clinical Trial Analysis
- Pharmacological Interventions
Background:
- Clinical trials are crucial for patient management, but hypotheses often stem from limited observational studies.
- Underrepresentation of women in studies is a concern, particularly as elderly women constitute a significant portion of hypertensive patients.
- Hypertension itself may cause symptoms like headaches, beyond severe outcomes like mortality.
Purpose of the Study:
- To review current clinical trial findings and their implications for hypertension management.
- To address the underrepresentation of women in hypertension research.
- To evaluate the efficacy and safety of various antihypertensive drug classes.
Main Methods:
- Review of findings from landmark studies like MICROHOPE and ALLHAT.
- Analysis of meta-analyses on blood pressure reduction in the elderly.
- Examination of studies on angiotensin-converting enzyme inhibitors, calcium antagonists, and statins.
Main Results:
- Angiotensin-converting enzyme inhibition (ramipril) showed benefits in diabetic patients (MICROHOPE).
- Doxazosin was associated with increased heart failure rates compared to diuretics (ALLHAT).
- Calcium antagonists were found to be non-inferior to diuretics for hard endpoints; statins lowered blood pressure in hypertensive, hypercholesterolemic patients.
Conclusions:
- Meta-analyses highlight the importance of blood pressure reduction in the elderly.
- Controversy remains regarding the first-line use of calcium antagonists.
- Current treatment recommendations may inadequately manage a large number of hypertensive patients with monotherapy.
Abstract:
Clinical trials continue to guide patient management. However, the hypotheses generally come from observational studies. Studies on women continue to be too little and too few, particularly in light of the fact that most elderly hypertensive patients are likely to be women. Attention has been drawn to the possibility that hypertension per se may engender symptoms such as headache for example, in addition to harder endpoints such as death. The MICROHOPE study, which was not a blood pressure-lowering study, showed that angiotensin converting enzyme inhibition with ramipril in diabetic patients provided the same beneficial effects previously published for the HOPE study. The doxazosin arm of the ALLHAT study was terminated by the data monitoring and safety board because the doxazosin-treated patients developed congestive heart failure at a greater rate than diuretic-treated patients. Two extensive studies testing two different classes of calcium antagonists against primarily diuretic-based treatment showed that the calcium antagonists were no less effective in terms of preventing hard endpoints. A small, but impressive cross-over study testing the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, against placebo showed that statin treatment lowers blood pressure in hypercholesterolemic patients with hypertension. Meta- analyses emphasized the value of blood pressure reduction in the elderly and added to the controversy and confusion about the role of calcium antagonists in the first-line treatment of hypertension. The point may be moot since with the current recommendations few hypertensive patients will be adequately treated with a single agent.